← Back to Search

Automated Insulin Delivery

Hybrid closed-loop (HCL) automated insulin delivery (AID) for Diabetes

N/A
Waitlist Available
Led By Francisco Pasquel, M.D., M.P.H
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients ≥18 years of age with insulin-treated T1 or Type 2 diabetes mellitus (T2DM) admitted to general (non-intensive care) medical-surgical hospital service requiring inpatient insulin therapy.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 days (or hospital discharge if before 10 days)
Awards & highlights

Study Summary

This study is evaluating whether a new type of insulin pump may help people with diabetes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 days (or hospital discharge if before 10 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 days (or hospital discharge if before 10 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Time Sensor Glucose is Within Target Glucose Range
Percentage of Time Spent in HCL After CGM Sensor Meets Initial Validation Criteria
Secondary outcome measures
Frequency of Setting Adjustments for Clinically-important Hypoglycemia (<54 mg/dL) to Basal Rate
Frequency of Setting Adjustments for Clinically-important Hypoglycemia (<54 mg/dL) to Insulin Carb Ratio (ICR)
Frequency of Setting Adjustments for Clinically-important Hypoglycemia (<54 mg/dL) to Insulin Sensitivity Factor (ISF)
+23 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Hybrid closed-loop (HCL) automated insulin delivery (AID)Experimental Treatment1 Intervention
Hybrid closed-loop (HCL) automated insulin delivery (AID) using the Omnipod 5/Horizon HCL system with remote monitoring and device operation capabilities will be deployed to hospitalized patients admitted to the general medical/surgical floor with diabetes (type 1 or type 2) requiring insulin therapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
The Omnipod 5/Horizon HCL system
2021
N/A
~30

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,640 Previous Clinical Trials
2,560,674 Total Patients Enrolled
32 Trials studying Diabetes
16,846 Patients Enrolled for Diabetes
Insulet CorporationIndustry Sponsor
20 Previous Clinical Trials
19,348 Total Patients Enrolled
Jaeb Center for Health ResearchOTHER
153 Previous Clinical Trials
34,889 Total Patients Enrolled
2 Trials studying Diabetes
1,955 Patients Enrolled for Diabetes

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What site did they apply to?
Stanford University School of Medicine
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Automated Insulin Delivery for INpatients With DysGlycemia (AIDING) Feasibility
Francisco Pasquel 2021. "Automated Insulin Delivery for INpatients With DysGlycemia (AIDING) Feasibility". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04714216.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top